Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the biggest names in the biotechnology sector. The company has already-approved assets (of which there are six so far) and pipeline-based development drugs (of which there are around 15 right now) designed to target a whole host of different indications, from eye disease to heart disease, to pain, cancer, infectious diseases and rare diseases.
In Johnson & Johnson news, the stock is down 1.3% over the last five trading days, and that makes this the perfect time to buy this dividend aristocrat…
The pullback was caused by two analysts downgrading Johnson & Johnson (NYSE: JNJ) on July 21, but analysts simply don’t know how to value JNJ stock.
BTIG Research downgraded JNJ from “Neutral” to....More>>>
Seemingly nothing can stop the marijuana industry, or marijuana stocks, at the moment.
Over the past couple of years, we’ve witnessed a number of major milestones for the cannabis industry. For example, in 2012, Colorado and Washington became the first states where a majority of voters legalized the sale of recreational marijuana to adults ages 21 and up. Since then, an additional six....More>>>
Pebblebrook Hotel Trust (NYSE:PEB) is a company that was designed to have a finite life, and appears to have just started its slow decline into old age. Founded late in 2009 to acquire distressed hotel assets in major coastal metros, the apparent timing of the company’s deal-making borders on prescient, given we now have the benefit of hindsight. Chairman and CEO Jon Bortz, who left LaSalle....More>>>
Stocks sunk today as election uncertainty weighs on investor sentiment.
The S&P 500 fell 0.7% to 2,097.94 today, while the Dow Jones Industrial Average declined 77.46 points, or 0.4% to 17,959.64. The Nasdaq Composite fell 0.9% to 5,105.57.
It was the seventh consecutive drop for the S&P 500, its longest losing streak since 2011.
Despite the recent....More>>>
IMAGE SOURCE: Adobe Systems Incorporated.
Shares ofAdobe Systems (NASDAQ:ADBE)climbed10.4% in 2016,according to data from S&P Global Market Intelligence, as the creative software specialist began to enjoy the fruits of its transition away from traditional, license-based software and toward a cloud-based subscription model.
In contrast to its often....More>>>